Autonomix Medical (NASDAQ:AMIX – Get Free Report) and Nuwellis (NASDAQ:NUWE – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.
Institutional & Insider Ownership
10.8% of Autonomix Medical shares are held by institutional investors. Comparatively, 3.1% of Nuwellis shares are held by institutional investors. 6.2% of Autonomix Medical shares are held by insiders. Comparatively, 20.1% of Nuwellis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Autonomix Medical and Nuwellis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Autonomix Medical | N/A | -213.42% | -172.57% |
| Nuwellis | -202.83% | -1,367.63% | -202.97% |
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Autonomix Medical | N/A | N/A | -$11.41 million | ($4.65) | -0.14 |
| Nuwellis | $8.17 million | 0.44 | -$11.16 million | ($107.91) | -0.02 |
Nuwellis has higher revenue and earnings than Autonomix Medical. Autonomix Medical is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings and target prices for Autonomix Medical and Nuwellis, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Autonomix Medical | 1 | 1 | 1 | 0 | 2.00 |
| Nuwellis | 1 | 0 | 1 | 0 | 2.00 |
Autonomix Medical currently has a consensus target price of $5.00, suggesting a potential upside of 675.55%. Given Autonomix Medical’s higher possible upside, equities analysts clearly believe Autonomix Medical is more favorable than Nuwellis.
Volatility and Risk
Autonomix Medical has a beta of -2.88, suggesting that its share price is 388% less volatile than the S&P 500. Comparatively, Nuwellis has a beta of -0.17, suggesting that its share price is 117% less volatile than the S&P 500.
Summary
Autonomix Medical beats Nuwellis on 6 of the 11 factors compared between the two stocks.
About Autonomix Medical
Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.
About Nuwellis
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Receive News & Ratings for Autonomix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autonomix Medical and related companies with MarketBeat.com's FREE daily email newsletter.
